dallas glp-1 lawsuit Wegovy® Navigating The GLP-1 Litigation Landscape

Thats a BFD, since micronutrient deficiencies and muscle and bone loss are all very real possibilities when on these medications

According to the DMHCs findings, Blue Shield issued contradictory determinations, denying coverage in one communication while approving it in another

The defense also suggests that they will aggressively defend Wegovy lawsuits that allege gastroparesis without objective testing confirming the diagnosis

less than a minor fraction undergoes metabolic activation

Keywords: cardiovascular disease, chronic kidney disease, diabetes, GLP1 receptor agonist 1

This persistent elevation of unbound bilirubin may pose a risk, particularly in neonates and pregnant individuals [160]